FcgammaRIIa-H ADCP Bioassay Effector Cells, Propagation Model
Measure Activity of Antibodies and Other Biologics that Bind and Activate Fc?RIIa
Antibody-dependent cell-mediated phagocytosis (ADCP) is an important mechanism of action (MOA) of therapeutic antibodies. In vivo, ADCP can be mediated by monocytes, macrophages, neutrophils and dendritic cells via Fc?RIIa, Fc?RI and Fc?RIIIa. While all three receptors can participate in ADCP, Fc?RIIa is believed to be the predominant Fc? receptor involved in this process.
The Fc?RIIa-H ADCP Reporter Bioassay is a biologically relevant MOA-based assay that can be used to measure the potency and stability of antibodies and other biologics that specifically bind and activate Fc?RIIa. The assay consists of Jurkat cells stably expressing human Fc?RIIa-H (the high-affinity H131 variant) and NFAT-induced luciferase.
The bioassay is prequalified according to ICH guidelines and shows the precision, accuracy and linearity required for routine use in potency and stability studies. The bioassay workflow is simple and robust, compatible with 96-well and 384-well plate formats, and unlike traditional primary cell-based assays, amenable for use in quality-controlled drug development settings.
Fc?RIIa-H ADCP Effector Bioassay Effector Cells, Propagation Model
ADCP Bioassay Effector Cells, Propagation Model, allows propagation and banking of the ADCP Bioassay Effector Cells. Bio-Glo™ Luciferase Assay System is the required reagent for use with ADCP Bioassay Effector Cells, Propagation Model.
Fc?RIIa-H ADCP Bioassay Effector Cells, Propagation Model Technical Manual
PDF (1 MB)
Certificate of AnalysisLookup Certificate of Analysis
For Research Use Only. Not for Use in Diagnostic Procedures.